No significant impact on HCC recurrence was found for the study size (p = 0.49), mean time elapsed from HCC curative treatment to DAA therapy (p = 0.32), mean follow-up duration (p = 0.58), mean size of previous HCC (p = 0.46), proportion of patients with >1 previous HCC (p = 0.92), or mean baseline alpha-fetoprotein (AFP) level (p = 0.50). This evidence concerns the gene AFP and hepatocellular carcinoma.